This is Prospective, Multi-centre, Open-labelled, Randomized, Phase II study seamlessly followed by a Phase III study to evaluate the Safety, Tolerability and Immunogenicity of GEMCOVAC-OM as a booster in Subjects 18 years of age and older. Thus, completion of subject diary is very important as this information will help the study doctor to assess your health post vaccination and provide appropriate treatment (if required).
Show More
